Regulatory China’s NMPA approves Akeso’s gumokimab for plaque psoriasis Pharmaceutical Business ReviewThe approval is based on data from one pivotal Phase III trial (AK111-301) and three additional supportive studies.Immunology & InflammationRead full story pharminent June 12, 2026 (Last updated: June 19, 2026) Pharmaceutical Business Review The approval is based on data from one pivotal Phase III trial (AK111-301) and three additional supportive studies. Immunology & Inflammation Read full story Post navigation Previous: How Medicare Advantage Rebates Disadvantage Medicare’s Stand-Alone Drug Plan MarketNext: Novo Nordisk comeback stirs as Wegovy pill wins UK approval Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026